Cargando…

Are We Ready For “Triplet” Therapy in Higher-Risk MDS?

Higher-risk Myelodysplastic Syndromes/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbidities. Outside of transplant, azacitidine and decitabine remain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brunner, Andrew M., Platzbecker, Uwe, DeZern, Amy E., Zeidan, Amer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Academy for Clinical Hematology (IACH) 2023
Materias:	Perspective Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625655/ https://www.ncbi.nlm.nih.gov/pubmed/37933301 http://dx.doi.org/10.46989/001c.88301

Ejemplares similares

Editorial: Advancing Science for Clinical Care in MDS
por: Figueroa, Maria E., et al.
Publicado: (2022)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
por: Komrokji, Rami S., et al.
Publicado: (2020)

Are We Ready for Migrastatics?
por: Solomon, Jonathan, et al.
Publicado: (2021)

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
por: Germing, Ulrich, et al.
Publicado: (2023)

Controversies on the Consequences of Iron Overload and Chelation in MDS
por: Vinchi, Francesca, et al.
Publicado: (2020)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Are We Ready to Implement Circadian Hygiene Interventions and Programs?
por: Moreno, Claudia R. C., et al.
Publicado: (2022)

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
por: Garcia-Manero, Guillermo, et al.
Publicado: (2022)

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
por: Brunner, Andrew M., et al.
Publicado: (2022)

The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies?
por: Heidel, Florian H., et al.
Publicado: (2021)

Are we ready to build health systems that consider the climate?
por: Mayhew, Susannah, et al.
Publicado: (2014)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
por: Komrokji, Rami S., et al.
Publicado: (2023)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Diced Triplets Expose Neurons to RISC
por: Rudnicki, Dobrila D., et al.
Publicado: (2012)

Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes
por: Götze, Katharina S., et al.
Publicado: (2018)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2022)

P705: AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX
por: Bains, Amanpreet, et al.
Publicado: (2023)

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
por: Stahl, Maximilian, et al.
Publicado: (2023)

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
por: Kuendgen, A., et al.
Publicado: (2020)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
por: DeZern, A., et al.
Publicado: (2022)

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts
por: Choi, In Young, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
por: Zhou, Jun, et al.
Publicado: (2021)

Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’
por: Dhaese, Sofie A. M., et al.
Publicado: (2022)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
por: Brunner, Andrew M., et al.
Publicado: (2022)

How sequence alterations enhance the stability and delay expansion of DNA triplet repeat domains
por: Völker, Jens, et al.
Publicado: (2023)

Harvesting triplet excitons for near-infrared electroluminescence via thermally activated delayed fluorescence channel
por: Yu, You-Jun, et al.
Publicado: (2021)

Person-first language: are we practicing what we preach?
por: Crocker, Amy F, et al.
Publicado: (2019)

Can we make the preparation of MDS more efficient?
por: Salvachua, B
Publicado: (2019)

Risk stratification in therapy-related myelodysplastic syndromes
por: Zeidan, Amer M.
Publicado: (2017)

Evaluating Collaborative Readiness for Interdisciplinary Flood Research
por: Tate, Eric, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qgpkq68d2jlssem66agprvugmi